PER-031-20尚未招募未知
PHASE 2 STUDY OF EFFICACY AND SAFETY OF PLASMA FROM CONVALESCENT PATIENTS WITH COVID-19 IN PATIENTS WITH MODERATE DISEASE (AUNA 20-01)
ONCOSALUD S.A.C.,0 个研究点目标入组 0 人开始时间: 2020年7月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •- Patients of both sexes ≥ 18 years
- •- Patient with a confirmed diagnosis of COVID-19 using moderately classified nasal and pharyngeal swab PCR tests, with some of the following symptoms:
- •Dyspnea or respiratory distress
- •Respiratory rate> 22 breaths / min
- •Arterial oxygen saturation <95% in ambient air
- •Alteration of the level of consciousness
- •Low blood pressure or shock
- •Clinical and / or radiological signs of pneumonia
- •Lymphocyte count less than 1000 cel / uL
- •- Acceptance of participation by signing an informed consent.
- •- That it is not participating in another interventional study for COVID-19.
排除标准
- •- Patients with a history of previous transfusion allergic reaction.
- •- Pregnant or lactating women (since there are no studies demonstrating their safety in pregnant and / or lactating women).
- •- Patients who have received other types of immunoglobulin therapy in the previous 30 days.
- •- Pediatric patient.
研究者
相似试验
已完成
2 期
A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers: REZOLVEACTRN12611000801910niversity of Sydney24
进行中（未招募）
1 期
A PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF RTA 408 IN PATIENTS WITH MITOCHONDRIAL MYOPATHYEUCTR2014-003501-15-DKReata Pharmaceuticals, Inc.52
已完成
2 期
safety and efficacy of homoeopathic remedy EpiphaniQ in adult patients with mild to moderate COVID-19:CTRI/2021/06/034404EpiphaniQ LLP
招募中
1 期
Safety and efficacy of potentised forms of cisplatin and docetaxelCTRI/2020/05/025045Central Council for Research in Homoeopathy
已完成
不适用
Phase II study evaluating efficacy and safety of peripheral blood stem cell harvest with bortezomib for multiple myelomaMultiple MyelomaJPRN-UMIN000010258Fourth Department of Internal Medicine, Sapporo Medical University, School of Medicine30